![]() |
市场调查报告书
商品编码
1471139
干细胞市场:按类型、来源、应用、最终用户划分 - 2024-2030 年全球预测Stem Cells Market by Type (Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell), Source (Allogenic, Autologous), Application, End-user - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年干细胞市场规模为136.6亿美元,预计2024年将达到150.5亿美元,2030年将达到279.9亿美元,复合年增长率为10.79%。
干细胞市场由用于研究、开发和医疗应用的各种产品和服务组成。这包括销售干细胞株、用于操纵和分析干细胞的设备,以及与干细胞库相关的服务以及在各种疾病治疗中的应用。干细胞在再生医学领域有着广泛的应用,包括帕金森氏症、阿兹海默症、糖尿病和心臟病。它对于各种癌症治疗方法的开发也至关重要。最终用户包括直接对患者进行干细胞治疗的研究机构、生技公司、製药公司、医院和诊所。干细胞市场的成长是由干细胞研究资金的增加、再生治疗需求的增加以及使干细胞治疗更容易获得和有效的技术进步所推动的。此外,全球慢性病的盛行率不断上升,需要开发创新的治疗方法,并推动对干细胞领域的进一步投资。然而,胚胎干细胞研究存在伦理问题,包括干细胞治疗的高成本、需要训练有素的人员、干细胞治疗的免疫排斥的可能性以及製造干细胞产品的复杂性,这些都阻碍了胚胎干细胞研究的发展。治疗的普及。同时,干细胞市场最大的商机在于新药发现平台的开发、个人化医疗的应用以及干细胞储存和分析的技术创新。扩大诱导性多功能干细胞(iPS 细胞) 的治疗应用以及利用干细胞进行组织和器官再生的 3D 生物列印技术的进步也是值得探索的领域。
主要市场统计 | |
---|---|
基准年[2023] | 136.6亿美元 |
预测年份 [2024] | 150.5亿美元 |
预测年份 [2030] | 279.9亿美元 |
复合年增长率(%) | 10.79% |
由于道德和监管障碍较低,成体干细胞的使用正在增加
成体干细胞是胚胎发育后存在于全身的未分化细胞。存在于骨髓、血液、脑部和肌肉组织。成体干细胞是多功能的,可以发展成多种细胞类型,但与多功能能干细胞相比这是有限的。成体干细胞主要透过骨髓移植用于治疗多种疾病,包括血液疾病。人类胚胎干细胞 (hESC) 源自于胚囊的内细胞群,囊胚胚胎着床前胚胎的早期阶段。这些多功能细胞可以分化成体内的所有细胞类型,提供广泛的治疗可能性。 hESC 具有分化成任何细胞类型的能力,对于了解人类早期发育、遗传疾病和药物筛检具有不可估量的价值。诱导性多功能干细胞(iPSC)是一种透过引入特定基因从非多功能细胞(通常是成体细胞)合成衍生的干细胞。 iPSC 在再生医学领域前景广阔,因为它们可以在体内生成任何类型的细胞,而不会出现与 hESC 相关的伦理问题。干细胞市场多种多样,每种干细胞都有独特的优势,但也面临不同的挑战。成体干细胞广泛存在,伦理和监管障碍较低,但其分化潜力有限。人类胚胎干细胞由于其多功能而具有巨大的治疗潜力,但伦理争论和限制性法律阻止其在许多国家的使用。诱导性多功能干细胞(干细胞)虽然是一项新技术,可提供量身定制的治疗方法并避免伦理限制,但需要进行大量研究以确保临床应用的安全性和有效性。
扩大干细胞在发展应用诊断模型的应用
诊断领域是干细胞应用极为重要的领域,对于各种疾病的早期发现和监测非常有用。干细胞正在帮助开发模拟人类疾病的诊断模型,使研究人员能够了解病理学并测试新的诊断方法。对早期准确疾病诊断的需求不断增加,推动了对涉及干细胞的创新诊断解决方案的需求。干细胞在药物发现和药物开发中发挥创新作用。提供人类特异性模型有可能透过减少对动物实验的依赖并提高预测药物反应的准确性来彻底改变药物筛检过程。製药业降低成本和增加有效药物管道的压力正在推动干细胞技术在药物发现和药物开发中的采用。再生医学是干细胞最有前景的应用领域,具有治癒受损组织和器官的潜力,并为以前无法治癒的疾病提供解决方案。再生医学领域正在利用干细胞的独特能力来突破传统医学的界限。对再生医学的需求是由患者主导的,通常针对治疗选择有限的情况,例如脊髓损伤、烧烫伤和心臟疾病,因此迫切需要新的治疗方法。
区域洞察
在美国,干细胞市场是由高水准的研究投资和强大的专利环境所推动的。凭藉强大的法规结构,研究机构和公司处于干细胞研究和临床试验的前沿。加拿大消费者越来越了解干细胞治疗的潜在好处,从而推动了需求的成长。然而,该市场的特点是对监管核准和专利申请采取谨慎态度。南美干细胞市场仍在发展中,但由于医疗基础设施投资增加和医疗旅游业兴起,预计将出现成长。由于成熟的製药业和有利的政府政策,欧洲是干细胞的重要市场。欧盟 (EU) 有关干细胞研究的严格法规确保道德实践和高品质标准,资金和合作研究机会正在促进市场成长。瑞士、德国、英国和法国等国家对干细胞研究有着非常支持的氛围,拥有众多的跨国合作关係和大量资金。中东地区对干细胞研究的兴趣和投资正在增长,特别是在沙乌地阿拉伯和以色列等以医疗创新而闻名的国家。非洲的干细胞市场仍在发展但前景广阔,而南非则处于领先地位。在人口老化加剧、医疗成本上升以及政府支持政策的背景下,亚太地区干细胞市场正在快速开拓。由于国家主导的措施和对生物技术的大量投资,中国的干细胞市场正在迅速扩大。日本以其前瞻性的监管政策而闻名,尤其是再生医学的快速核准制度。日本消费者对干细胞疗法的高度信任很大程度上归功于政府的广泛支持和有利于技术进步的文化。印度干细胞市场正在兴起,研究倡议数量不断增加,消费者兴趣不断增长。
FPNV定位矩阵
FPNV定位矩阵对于评估干细胞市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对干细胞市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,以获得市场竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争评估及资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行综合评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1. 干细胞市场的市场规模与预测是多少?
2.干细胞市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些?
3. 干细胞市场的技术趋势和法规结构是什么?
4.干细胞市场主要厂商的市场占有率是多少?
5. 进入干细胞市场的合适型态和策略性手段是什么?
[187 Pages Report] The Stem Cells Market size was estimated at USD 13.66 billion in 2023 and expected to reach USD 15.05 billion in 2024, at a CAGR 10.79% to reach USD 27.99 billion by 2030.
The stem cell market comprises various products and services used for the research, development, and application of stem cells in medical therapies. It includes the sale of stem cell lines, instruments used in the manipulation and analysis of stem cells, and services related to stem cell banking and therapeutic applications across various disease treatments. Stem cells find extensive applications in regenerative medicine for diseases such as Parkinson's, Alzheimer's, diabetes, and heart disease. They also are vital in developing various cancer treatments. End-users include research institutes, biotech companies, pharmaceutical corporations, hospitals, and clinics applying stem cell therapies directly to patients. Growth in the stem cell market is primarily driven by the increased funding for stem cell research, rising demand for regenerative treatment options, and advancements in technology that make stem cell therapies more accessible and effective. Additionally, the growing incidence rates of chronic diseases worldwide necessitate the development of innovative treatment approaches, fostering further investment in the stem cell sector. However, the adoption of stem cells is hindered by ethical issues covering embryonic stem cell research, the high costs of stem cell therapies, the need for adequately trained personnel, the potential immune rejection of stem cell therapies, and the complexity of manufacturing stem cell products. On the other hand, the most significant opportunities in the stem cell market lie in the development of new drug discovery platforms, applications in personalized medicine, and technological innovations in stem cell preservation and analysis. Expansion of the therapeutic applications of induced pluripotent stem cells (iPSCs) and advancements in 3D bioprinting utilizing stem cells for tissue and organ regeneration are other areas for exploration.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 13.66 billion |
Estimated Year [2024] | USD 15.05 billion |
Forecast Year [2030] | USD 27.99 billion |
CAGR (%) | 10.79% |
Type: Increasing usage of adult stem cells due to its fewer ethical and regulatory hurdles
Adult stem cells are undifferentiated cells located throughout the body after embryonic development. They can be discovered in bone marrow, blood, brain, and muscle tissues. Adult stem cells are multipotent, meaning they can develop into more than one cell type but are limited compared to pluripotent stem cells. Adult stem cells are primarily used to treat various diseases, including hematological conditions, through bone marrow transplants. Human embryonic stem cells (hESCs) are sourced from the internal cell group of a blastocyst, an early-stage pre-implantation embryo. These pluripotent cells can develop into any cell type of the body, offering broad therapeutic potential. With their ability to differentiate into any cell type, hESCs are immensely valuable for understanding early human development, genetic diseases, and drug screening. Induced pluripotent stem cells (iPSCs) are a kind of stem cell synthetically derived from non-pluripotent cells, typically adult somatic cells, by introducing certain genes. iPSCs hold promise in regenerative medicine because they can give rise to every cell type in the body without the ethical issues associated with hESCs. iPSCs are particularly promising for personalized medicine, as they can be derived from a patient's cells, reducing the risk of rejection. The stem cell market is diverse, with each type of stem cell offering unique benefits and facing distinct challenges. Adult stem cells are widely used and have fewer ethical and regulatory hurdles but offer limited differentiation potential. Human embryonic stem cells show vast therapeutic potential given their pluripotency, but their use is impaired by considerable ethical debates and restrictive legislation in many countries. Induced pluripotent stem cells, although a newer technology, provide tailored treatments and avoid ethical constraints but require significant research and development to ensure their safety and efficacy in clinical applications.
Application: Expanding the application of stem cells in developing diagnostic models
The diagnostic segment is a crucial area within stem cell applications, facilitating the early detection and monitoring of various diseases. Stem cells are instrumental in developing diagnostic models that mimic human diseases, enabling researchers to understand pathology and test new diagnostic methods. There's a growing need for accurate disease diagnosis early, subsequently increasing the demand for innovative diagnostic solutions involving stem cells. Stem cells play a transformative role in drug discovery and development. They have the potential to revolutionize the drug screening process by providing human-specific models, which can lower the dependency on animal testing and improve the predictive accuracy of drug responses. The pharmaceutical industry's pressure to reduce costs and increase the pipeline of effective drugs is a driving force behind the adoption of stem cell technologies in this drug discovery and development. Regenerative medicine is the most promising application of stem cells, potentially healing damaged tissues and organs and offering solutions for previously untreatable conditions. The regenerative medicine sector is pushing the boundaries of traditional medical treatments, harnessing the unique capabilities of stem cells. The demand in regenerative medicine is patient-driven, often for conditions with limited treatment options, such as spinal cord injuries, burns, and heart diseases, creating a significant need for novel therapeutic approaches.
Regional Insights
In the United States, the stem cell market is driven by high levels of investment in research and a strong patent landscape. With a robust regulatory framework, institutions and companies are at the forefront of stem cell research and clinical trials. Canadian consumers are becoming increasingly knowledgeable about the potential benefits of stem cell therapies, prompting a rise in demand. However, the market is also characterized by a cautious approach to regulatory approvals and patenting. The stem cell market in South America is still in the developmental phase but is expected to grow due to growing investment in healthcare infrastructure and rising medical tourism. Europe is a significant market for stem cells, with the presence of a well-established pharmaceutical industry and favorable government policies. The European Union's strict regulations on stem cell research ensure ethical practices and high-quality standards, while funding and collaboration opportunities contribute to the market growth. Countries such as Switzerland, Germany, the UK, and France showcase a highly collaborative atmosphere for stem cell research, with numerous cross-border partnerships and substantial funding. The Middle East has shown increasing interest in stem cell research and investment, particularly in countries, including Saudi Arabia, or Israel, which is known for its innovation in medical technology. Africa has a nascent but promising stem cell market, with South Africa at the forefront regarding research efforts and regulatory structure. The APAC region is witnessing rapid development in the stem cell market due to the increasing geriatric population, rising healthcare expenditure, and supportive government policies. China's stem cell market is expanding rapidly due to state-led initiatives and significant investment in biotechnology. Japan is known for its forward-looking regulatory policies, especially the fast-track approval system for regenerative medicine. Japanese consumers highly trust stem cell treatments, largely due to extensive government backing and a culture that favors technological advancement. India's stem cell market is emerging, with an increasing number of research initiatives and growing consumer interest.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Stem Cells Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stem Cells Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Stem Cells Market, highlighting leading vendors and their innovative profiles. These include Advanced Cell Technology, Inc., AlloSource, Inc., Anterogen Co., Ltd., Athersys Inc., Becton, Dickinson and Company, Bioheart Inc., Biorestorative Therapies Inc., BioTime, Inc., BrainStorm Cell Therapeutics Inc., Celgene Corporation, Cellartis AB, CellGenix GmbH, Cellular Engineering Technologies Inc., Gamida Cell Ltd, GenScript Biotech Corporation, Gilead Sciences, Inc., Holostem Terapie Avanzate Srl by Fondazione Enea Tech e Biomedical,, JCR Pharmaceuticals Co., Ltd., Lonza Group Ltd, Novartis AG, NuVasive Inc., Pluristyx, Inc., RTI Surgical, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Stem Cells Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stem Cells Market?
3. What are the technology trends and regulatory frameworks in the Stem Cells Market?
4. What is the market share of the leading vendors in the Stem Cells Market?
5. Which modes and strategic moves are suitable for entering the Stem Cells Market?